Analysis of the Mechanism and Prognostic Factors of Breast Cancer

Mingxuan Lyu

doi:10.62051/ijphmr.v3n3.04

Authors

Mingxuan Lyu

DOI:

https://doi.org/10.62051/ijphmr.v3n3.04

Keywords:

Breast cancer, Molecular subtypes, Endocrine therapy, Metabolic reprogramming

Abstract

Breast cancer ranks among the most frequently diagnosed cancers in women worldwide, driven by a multifaceted interplay of genetic, hormonal, environmental, and lifestyle influences. This paper delves into the underlying mechanisms of breast cancer progression, highlighting its molecular features and the contributions of diverse factors such as lifestyle behaviors, hormonal imbalances, and inherited genetic risks. Additionally, the biological behaviors of Luminal and HER2-enriched subtypes are discussed, along with the latest research advancements in precision medicine tailored to these subtypes. By integrating multi-omics data, this work uncovers the heterogeneity within HER2 subtypes and identifies new therapeutic targets, offering critical insights for personalized breast cancer diagnosis and treatment. The paper also reviews the most recent developments in surgery, endocrine therapy, chemotherapy, and immunotherapy, highlighting their roles in improving patient outcomes. Moreover, it explores the potential of metabolic reprogramming and targeted therapies as innovative strategies to further enhance prognosis. Looking ahead, multidisciplinary collaboration and technological advances are expected to play a pivotal role in refining the precision of breast cancer diagnosis and therapy.

References

[1] Zeinomar, N., Knight, J. A., Genkinger, J. M., et al. (2019). Alcohol consumption, cigarette smoking, and familial breast cancer risk: Findings from the Prospective Family Study Cohort (ProF-SC). Breast Cancer Res., 21(1), 128.

[2] Chen, X., Wang, Q., Zhang, Y., et al. (2019). Physical activity and risk of breast cancer: A meta-analysis of 38 cohort studies in 45 study reports. Value Health, 22(1), 104–128.

[3] Uhomoibhi, T. O., Okobi, T. J., Okobi, O. E., et al. (2022). High-fat diet as a risk factor for breast cancer: A meta-analysis. Cureus, 14(12), e32309.

[4] Li, Y., & Ma, L. (2020). Exposure to solar ultraviolet radiation and breast cancer risk: A dose-response meta-analysis. Medicine (Baltimore), 99(45), e23105.

[5] Lee, J. J., Jung, Y. L., Cheong, T. C., et al. (2023). ERα-associated translocations underlie oncogene amplifications in breast cancer. Nature, 618(7967), 1024–1032.

[6] Scabia, V., Ayyanan, A., De Martino, F., et al. (2022). Estrogen receptor positive breast cancers have patient-specific hormone sensitivities and rely on progesterone receptor. Nat. Commun., 13(1), 3127.

[7] Hu, C., Hart, S. N., Gnanaolivu, R., et al. (2021). A population-based study of genes previously implicated in breast cancer. N. Engl. J. Med., 384(5), 440–451.

[8] Huang, R., & Zhou, P. K. (2021). DNA damage repair: Historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct. Target Ther., 6(1), 254.

[9] Tutt, A. N. J., Garber, J. E., Kaufman, B., et al. (2021). Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N. Engl. J. Med., 384(25), 2394–2405.

[10] Davidson, J. A., Cromwell, I., Ellard, S. L., et al. (2013). A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor-positive node-negative breast cancer. Eur. J. Cancer, 49(11), 2469–2475.

[11] Cardoso, F., Van't Veer, L. J., Bogaerts, J., et al. (2016). 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N. Engl. J. Med., 375(8), 717–729.

[12] Harbeck, N., & Gnant, M. (2017). Breast cancer. Lancet, 389(10074), 1134–1150.

[13] Stebbing, J., Shah, K., Lit, L. C., et al. (2018). LMTK3 confers chemo-resistance in breast cancer. Oncogene, 37(23), 3113–3130.

[14] Xu, Y., Zhang, H., Lit, L. C., et al. (2014). The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β₁. Sci. Signal., 7(330), ra58.

[15] Gong, Y., Ji, P., Yang, Y. S., et al. (2021). Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab., 33(1), 51–64.e9.

[16] Tarantino, P., Hamilton, E., Tolaney, S. M., et al. (2020). HER2-low breast cancer: Pathological and clinical landscape. J. Clin. Oncol., 38(17), 1951–1962.

[17] Yang, C., Ren, C., Jia, Y., et al. (2022). A machine learning-based alloy design system to facilitate the rational design of high entropy alloys with enhanced hardness. Acta Mater., 222, 117431.

[18] Wu, Q., Li, Q., Zhu, W., et al. (2021). Identification of autophagy-related long non-coding RNA prognostic signature for breast cancer. J. Cell Mol. Med., 25(8), 4088–4098.

[19] Tian, P., Zheng, J., Qiao, K., et al. (2024). scPharm: Identifying pharmacological subpopulations of single cells for precision medicine in cancers. Adv. Sci. (Weinh), 11, e2412419.

[20] Li, Y. W., Dai, L. J., Wu, X. R., et al. (2024). Molecular characterization and classification of HER2-positive breast cancer inform tailored therapeutic strategies. Cancer Res., 84(21), 3669–3683.

[21] DeSantis, C., Siegel, R., Bandi, P., et al. (2011). Breast cancer statistics, 2011. CA Cancer J. Clin., 61(6), 409–418.

[22] Esposito, E., Di Micco, R., & Gentilini, O. D. (2017). Sentinel node biopsy in early breast cancer: A review on recent and ongoing randomized trials. Breast, 36, 14–19.

[23] Vicini, F. A., Cecchini, R. S., White, J. R., et al. (2019). Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: A randomised, phase 3, equivalence trial. Lancet, 394(10215), 2155–2164.

[24] Kang, H. S., Kim, J. Y., Kim, J. J., et al. (2022). Diffusion kurtosis MR imaging of invasive breast cancer: Correlations with prognostic factors and molecular subtypes. J. Magn. Reson. Imaging, 56(1), 110–120.

[25] Modi, S., Jacot, W., Yamashita, T., et al. (2022). Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med., 387(1), 9–20.

[26] Schmid, P., Cortes, J., Dent, R., et al. (2022). Event-free survival with pembrolizumab in early triple-negative breast cancer. N. Engl. J. Med., 386(6), 556–567.